MSF urges EU to rid market of ‘avoidable suffering’ from SPCs

Médecins Sans Frontières (MSF) has warned that the European Commission’s commitment to the supplementary protection certificate (SPC) system risks undermining its promise to improve drug accessibility.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Africa

MSF urges South Africa to open access to COVID-19 generics

10 February 2022 Humanitarian organisation Médecins Sans Frontières has called for the South African government to seek the revocation of COVID-19-related patents granted to Eli Lilly and Moderna.

Generics

Lawyers warn of Irish Sea split over SPCs

17 December 2020 The UK is facing a divergence in supplementary protection certificate regulations across the Irish Sea post-Brexit.

Asia

MSF challenges Gilead patent application in China

21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

MSF urges EU to rid market of ‘avoidable suffering’ from SPCs

More on this story

Editor's picks

Editor's picks

More features